Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “High-risk Plasma Cell Neoplasms”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)UnknownNCT00526734
What this trial is testing

High-Dose Chemotherapy and Stem Cell Transplant in Treating Patients With Newly Diagnosed Stage I, Stage II, or Stage III Multiple Myeloma

Who this might be right for
Multiple Myeloma and Plasma Cell Neoplasm
Erasme University Hospital 100
Testing effectiveness (Phase 2)Study completedNCT00469209
What this trial is testing

Velcade, Trisenox, Vitamin C and Melphalan for Myeloma Patients

Who this might be right for
Myeloma
M.D. Anderson Cancer Center 60
Large-scale testing (Phase 3)Study completedNCT00417911
What this trial is testing

Efficacy of Bortezomib Consolidation After High-dose Melphalan With Stem Cell Support in Myeloma Patients

Who this might be right for
Multiple Myeloma
Nordic Myeloma Study Group 400
Testing effectiveness (Phase 2)Ended earlyNCT00005641
What this trial is testing

Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation

Who this might be right for
Chronic Myeloproliferative DisordersGraft Versus Host DiseaseLeukemia+2 more
H. Lee Moffitt Cancer Center and Research Institute
Testing effectiveness (Phase 2)Study completedNCT00458705
What this trial is testing

Bortezomib, Doxorubicin Hydrochloride Liposome, and Dexamethasone Followed by Thalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Multiple Myeloma

Who this might be right for
Multiple Myeloma and Plasma Cell Neoplasm
Memorial Sloan Kettering Cancer Center 45
Testing effectiveness (Phase 2)Looking for participantsNCT05597345
What this trial is testing

Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma

Who this might be right for
Smoldering Multiple Myeloma
University of Rochester 15
Testing effectiveness (Phase 2)Study completedNCT00110045
What this trial is testing

Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell Transplant

Who this might be right for
Cancer
European Organisation for Research and Treatment of Cancer - EORTC 171
Testing effectiveness (Phase 2)Study completedNCT01237951
What this trial is testing

High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic-Cell Support for Patients With Poor-Risk Myeloma

Who this might be right for
Myeloma
M.D. Anderson Cancer Center 75
Testing effectiveness (Phase 2)Study completedNCT00349778
What this trial is testing

High-Dose Sequential Therapy and Single Autologous Transplantation for Multiple Myeloma

Who this might be right for
Multiple Myeloma
Stanford University 102
Not applicableWithdrawnNCT00378781
What this trial is testing

Heparin or M-EDTA in Preventing Catheter-Related Infections and Blockages in Patients at High Risk for a Catheter-Related Infection

Who this might be right for
Cancer
M.D. Anderson Cancer Center
Testing effectiveness (Phase 2)UnknownNCT00508209
What this trial is testing

Bortezomib and High-dose Melphalan at Myeloma Relapse

Who this might be right for
Multiple Myeloma
Nordic Myeloma Study Group 50
Testing effectiveness (Phase 2)Study completedNCT02556931
What this trial is testing

Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies

Who this might be right for
Myelodysplastic SyndromeChronic Myelomonocytic LeukemiaSmall Lymphocytic Lymphoma+11 more
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 117
Testing effectiveness (Phase 2)Ended earlyNCT00818961
What this trial is testing

Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer

Who this might be right for
LeukemiaLymphomaMyelodysplastic Syndromes+1 more
Northside Hospital, Inc. 36
Testing effectiveness (Phase 2)Study completedNCT02874742
What this trial is testing

Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma

Who this might be right for
Multiple Myeloma
Janssen Research & Development, LLC 224
Large-scale testing (Phase 3)UnknownNCT00546988
What this trial is testing

Multi Centre Trial of DSMM for Newly Diagnosed Multiple Myeloma up to 60 Years

Who this might be right for
Multiple Myeloma
University of Wuerzburg 600
Testing effectiveness (Phase 2)Active Not RecruitingNCT04998786
What this trial is testing

A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse."

Who this might be right for
Multiple Myeloma at First Relapse
Nantes University Hospital 75
Early research (Phase 1)Ended earlyNCT02043860
What this trial is testing

Total Marrow Irradiation With High Dose Melphalan Prior to Autologous Transplant for Multiple Myeloma

Who this might be right for
Multiple Myeloma
University of Illinois at Chicago 3
Not applicableLooking for participantsNCT07205523
What this trial is testing

High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT)

Who this might be right for
Hematopoietic Stem Cell Transplantation (HSCT)Acute Myeloid Leukemia (AML)Leukemias, Acute Myeloid+12 more
Yigeng Cao,MD,PhD 1,000
Early research (Phase 1)Not Yet RecruitingNCT07114432
What this trial is testing

RN1201 Injection in Newly Diagnosed High-Risk Cytogenetic Multiple Myeloma

Who this might be right for
Newly Diagnosed High-Risk Cytogenetic Multiple Myeloma Patients Ineligible or Unwilling to Undergo ASCTNewly Diagnosed Multiple Myeloma (NDMM)
Tianjin Medical University Cancer Institute and Hospital 19
Very early researchUnknownNCT04617704
What this trial is testing

BCMA and CD19 Targeted Fast Dual CART for Chromosomal Abnomalities High-risk BCMA+ Multiple Myeloma

Who this might be right for
Multiple Myeloma
Shanghai Changzheng Hospital 15
Next Page